New Stem Cell Technologies Have Great Potential For Treating PD.
The researchers describe in a new article how newly developed stem cell technologies could be used to treat the disease and discuss the great promise, as well as the significant challenges, of stem cell treatment.
The most common PD treatment today is based on enhancing the activity of the nigrostriatal pathway in the brain with dopamine-modulating therapies, thereby increasing striatal dopamine levels and improving motor impairment associated with the disease.
However, this treatment has significant long-term limitations and side effects.
Stem cell technologies show promise for treating PD and may play an increasing role in alleviating at least the motor symptoms, if not others, in the decades to come.
"We are in desperate need of a better way of helping people with PD. It is on the increase worldwide. There is still no cure, and medications only go part way to fully treat incoordination and movement problems," said Claire Henchcliffe of Weill Cornell Medical College. "If successful, using stem cells as a source of transplantable dopamine-producing nerve cells could revolutionize care of the PD patient in the future. A single surgery could potentially provide a transplant that would last throughout a patient's lifespan, reducing or altogether avoiding the need for dopamine-based medications."
The authors have analyzed how newly developed stem cell technologies could be used to treat PD, and how clinical researchers are moving very quickly to translate this technology to early clinical trials.
In the past, most transplantation studies in PD used human cells from aborted embryos. While these transplants could survive and function for many years, there were scientific and ethical issues: fetal cells are in limited supply, and they are highly variable and hard to quality control. Only some patients benefited, and some developed side effects from the grafts, such as uncontrollable movements called dyskinesias.
Recent strides in stem cell technology mean that quality, consistency, activity, and safety can be assured, and that it is possible to grow essentially unlimited amounts of dopamine-producing nerve cells in the laboratory for transplantation.
This approach is now rapidly moving into initial testing in clinical trials.
The choice of starting material has also expanded with the availability of multiple human embryonic stem cell lines, as well as the possibilities for producing induced pluripotent cells, or neuronal cells from a patient's own blood or skin cells.
"We are moving into a very exciting era for stem cell therapy," said researcher Malin Parmar. "The first-generation cells are now being trialed and new advances in stem cell biology and genetic engineering promise even better cells and therapies in the future. There is a long road ahead in demonstrating how well stem cell-based reparative therapies will work, and much to understand about what, where, and how to deliver the cells, and to whom. But the massive strides in technology over recent years make it tempting to speculate that cell replacement may play an increasing role in alleviating at least the motor symptoms, if not others, in the decades to come."
"With several research groups, including our own centers, quickly moving towards testing of stem cell therapies for PD, there is not only a drive to improve what is possible for our patients, but also a realization that our best chance is harmonizing efforts across groups," said Henchcliffe. "Right now, we are just talking about the first logical step in using cell therapies in PD. Importantly, it could open the way to being able to engineer the cells to provide superior treatment, possibly using different types of cells to treat different symptoms of PD like movement problems and memory loss."
"This approach to brain repair in PD definitely has major potential, and the coming two decades might also see even greater advances in stem cell engineering with stem cells that are tailor -made for specific patients or patient groups," said Patrik Brundin of the Journal of Parkinson's Disease. "At the same time, there are several biological, practical, and commercial hurdles that need circumventing for this to become a routine therapy."
Citation: Claire Henchcliffe, Malin Parmar. Repairing the Brain: Cell Replacement Using Stem Cell-Based Technologies. Journal of Parkinson's Disease, 2018; 8 (s1): S131 DOI: 10.3233/JPD-181488
Contact: Claire Henchcliffe, email@example.com
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Stem Cells & Parkinson's Disease|
|Publication:||Stem Cell Research News|
|Date:||Feb 25, 2019|
|Previous Article:||Measles Virus Vector Used To Create More Efficient Way To Reprogram Stem Cells.|
|Next Article:||Trial Planned For Cell Therapy Derived From Engineered Stem Cell.|